​

Syros Pharmaceuticals (SYRS) Stock Forecast, Price Target & Predictions

OverviewFinancialsChartTranscripts

SYRS Stock Forecast

Syros Pharmaceuticals (SYRS) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $5.00, with a high of $5.00 and a low of $5.00. This represents a 24900.00% increase from the last price of $0.02.

- $1 $2 $3 $4 $5 $6 $7 $8 High: $5 Avg: $5 Low: $5 Last Closed Price: $0.02

SYRS Stock Rating

Syros Pharmaceuticals stock's rating consensus is Hold, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (44.44%), 5 Hold (55.56%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 9 0 5 4 Strong Sell Sell Hold Buy Strong Buy

SYRS Price Target Upside V Benchmarks

TypeNameUpside
StockSyros Pharmaceuticals24900.00%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$11.00
Last Closing Price$0.02$0.02$0.02
Upside/Downside--54900.00%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25--1--1
Mar, 25--3--3
Feb, 25--3--3
Jan, 25--3--3
Dec, 24--4--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 23, 2024Edward TenthoffPiper Sandler$5.00$2.47102.43%24900.00%
Jun 26, 2024Edward TenthoffPiper Sandler$13.00$5.70128.07%64900.00%
Jun 26, 2024Andrew FeinH.C. Wainwright$15.00$5.70163.16%74900.00%
Aug 09, 2022Mark BreidenbachOppenheimer$30.00$9.27223.62%149900.00%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024JMP SecuritiesMarket OutperformPerformdowngrade
Oct 23, 2024Piper SandlerOverweightOverweighthold
Jun 26, 2024Cowen & Co.BuyBuyhold
Jun 26, 2024Piper SandlerOverweightOverweighthold
Jun 26, 2024H.C. WainwrightBuyBuyhold
Jun 25, 2024JMP SecuritiesMarket OutperformMarket Outperformhold
Jan 05, 2023Piper SandlerOverweightOverweighthold
Sep 19, 2022Piper SandlerOverweightOverweighthold
Aug 09, 2022OppenheimerOutperformOutperformhold
May 17, 2022Alliance Global PartnersBuyBuyhold

Financial Forecast

EPS Forecast

$-20 $-16 $-12 $-8 $-4 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-18.64$-14.47$-10.71$-5.81-----
Avg Forecast$-16.99$-15.01$-9.37$-4.73$-1.58$-2.29$-2.32$-2.26$-2.45
High Forecast$-16.99$-15.01$-9.37$-4.58$-1.52$-2.15$-0.60$-0.65$-2.45
Low Forecast$-16.99$-15.01$-9.37$-4.88$-1.63$-2.42$-3.57$-3.32$-2.45
Surprise %9.71%-3.60%14.30%22.83%-----

Revenue Forecast

$0 $5M $10M $15M $20M $25M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$15.09M$23.49M$14.88M$9.94M-----
Avg Forecast$12.11M$20.48M$19.47M$11.53M$450.00K$5.00M$1.67M$1.67M$1.67M
High Forecast$12.11M$20.48M$19.47M$13.52M$450.00K$5.00M$1.67M$1.67M$1.67M
Low Forecast$12.11M$20.48M$19.47M$9.89M$450.00K$5.00M$1.67M$1.67M$1.67M
Surprise %24.62%14.66%-23.56%-13.82%-----

Net Income Forecast

$-500M $-400M $-300M $-200M $-100M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-85.83M$-90.47M$-49.30M------
Avg Forecast$-481.18M$-425.29M$-265.32M$-133.96M$-44.52M$-64.85M$-96.40M$-56.23M$-69.49M
High Forecast$-481.18M$-425.29M$-265.32M$-129.64M$-43.01M$-61.02M$-17.00M$-18.41M$-69.49M
Low Forecast$-481.18M$-425.29M$-265.32M$-138.27M$-46.04M$-68.68M$-101.12M$-94.04M$-69.49M
Surprise %-82.16%-78.73%-81.42%------

SYRS Forecast FAQ

Is Syros Pharmaceuticals stock a buy?

Syros Pharmaceuticals stock has a consensus rating of Hold, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Syros Pharmaceuticals is a neutral investment for most analysts.

What is Syros Pharmaceuticals's price target?

Syros Pharmaceuticals's price target, set by 9 Wall Street analysts, averages $5 over the next 12 months. The price target range spans from $5 at the low end to $5 at the high end, suggesting a potential 24900.00% change from the previous closing price of $0.02.

How does Syros Pharmaceuticals stock forecast compare to its benchmarks?

Syros Pharmaceuticals's stock forecast shows a 24900.00% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Syros Pharmaceuticals over the past three months?

  • April 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Syros Pharmaceuticals’s EPS forecast?

Syros Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2024 is $-1.58, marking a -72.81% decrease from the reported $-5.81 in 2023. Estimates for the following years are $-2.29 in 2025, $-2.32 in 2026, $-2.26 in 2027, and $-2.45 in 2028.

What is Syros Pharmaceuticals’s revenue forecast?

Syros Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2024 is $450K, reflecting a -95.47% decrease from the reported $9.94M in 2023. The forecast for 2025 is $5M, followed by $1.67M for 2026, $1.67M for 2027, and $1.67M for 2028.

What is Syros Pharmaceuticals’s net income forecast?

Syros Pharmaceuticals's net income forecast for the fiscal year ending in December 2024 stands at $-44.522M, representing a 0% decrease from the reported $0 in 2023. Projections indicate $-64.851M in 2025, $-96.4M in 2026, $-56.227M in 2027, and $-69.492M in 2028.